Forecast

The analysts' average price target is +5,15€ (+359,82%). The median is +5,15€ (+359,82%).

Buy	4
Hold	2
Sell	0

News Go to news feed

MaxCyte elects three directors and confirms auditor

At MaxCyte’s annual meeting, Patrick Balthrop, Cynthia Collins and Stanley Erck were elected as Class II directors. Shareholders confirmed CohnReznick LLP as the independent auditor for the fiscal year ending December 31, 2026. MaxCyte reported strong Q1 results, beat earnings and revenue forecasts, and again meets the Nasdaq minimum bid-price requirement, but despite a strong balance sheet it still has negative EBITDA and a 27% YTD share-price decline. » More on de.investing.com
MaxCyte misses Q4 2025 revenue and earnings forecasts

MaxCyte reported Q4 2025 revenue of $7.3 million and EPS of -$0.09, missing analysts’ expectations of $9.36 million and -$0.08. Full‑year revenue fell to $33 million from $38.6 million a year earlier, and core revenue growth remained weak. Gross margin improved to 78 percent and operating expenses declined by 12 percent; the company is debt‑free and expects a cash position of at least $136 million at the end of 2026. MaxCyte is banking on the new ExPERT‑DTx platform to drive revenue growth from the second half of 2026, but remains exposed to customer concentration and market uncertainties. » More on de.investing.com
MaxCyte receives NASDAQ notice after falling below minimum price requirement

MaxCyte received a notice from NASDAQ because its stock closed below $1.00 for 30 consecutive trading days, failing to meet the minimum price requirement under Rule 5450(a)(1). The listing remains in place for now; the company has until September 14, 2026 to regain compliance by posting a closing bid of $1.00 or higher for at least 10 consecutive trading days. If the requirements are not met, NASDAQ may grant an additional compliance period with a possible transfer to the Nasdaq Capital Market or a potential delisting, against which MaxCyte can file an appeal. » More on de.investing.com

Financials

In the last quarter, MAXCYTE INC DL-,01 had revenue of 6.37m€ and net profit of −7.78m€

(EUR)	Jun 2026	YoY
Revenue	+6.37m	11,73%
Gross profit	+4.90m	17,30%
Net profit	−7.78m	25,83%
EBITDA	−7.78m	17,14%

Fundamentals

Metric	Value
Market capitalization	+124.18m€
Number of shares	107.12m
52-week high/low	+1,60€ - +0,55€
Dividends	No
Beta	1,49
P/E ratio	−4,04
PEG ratio	−0,15
P/B ratio	+0,91
P/S ratio	+4,66

Company profile

MaxCyte, Inc. ist ein globales Life-Science-Unternehmen, das sich mit der Entdeckung, Entwicklung und Vermarktung von Zelltherapien der nächsten Generation beschäftigt. Zu den Produkten des Unternehmens gehören ExPERT ATx, ein statisches Elektroporationsgerät für die Transfektion in kleinem bis mittlerem Maßstab; ExPERT STx, ein Durchflusselektroporationsgerät für die Proteinproduktion und Arzneimittelentwicklung sowie für die Expression therapeutischer Targets für zellbasierte Assays; ExPERT GTx, ein Durchflusselektroporationsgerät für die Transfektion in großem Maßstab bei therapeutischen Anwendungen; und ExPERT VLx für das Zell-Engineering in sehr großen Mengen. Das Unternehmen bietet auch Einwegprozessoren (PAs) zur Verarbeitung und Elektroporation von Zellen sowie Zubehör zur Unterstützung der PAs, wie z. B. Elektroporationspufferlösungen und Softwareprotokolle. Das Unternehmen wurde 1998 gegründet und hat seinen Hauptsitz in Gaithersburg, Maryland.

Name	MAXCYTE INC DL-,01
CEO	Maher Masoud
Headquarters	Rockville, md USA
Website	maxcyte.com
Sector	Materials
Industry	Aerospace & Defense
IPO	10/15/2013
Employees	91